These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29770715)

  • 21.
    Babakhanlou R; DiNardo C; Borthakur G
    Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
    Klink AJ; Gajra A; Knoth RL; Marshall L; Hou Y; McBride A; Copher R
    Leuk Res; 2022 Nov; 122():106946. PubMed ID: 36108427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
    Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
    Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
    [No Abstract]   [Full Text] [Related]  

  • 24. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
    Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
    Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
    [No Abstract]   [Full Text] [Related]  

  • 25. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
    Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P
    Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positive First Trial of Enasidenib for AML.
    Cancer Discov; 2017 Aug; 7(8):OF1. PubMed ID: 28659444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.
    Montesinos P; Fathi AT; de Botton S; Stein EM; Zeidan AM; Zhu Y; Prebet T; Vigil CE; Bluemmert I; Yu X; DiNardo CD
    Blood Adv; 2024 May; 8(10):2509-2519. PubMed ID: 38507688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
    Risueño A; See WL; Bluemmert I; de Botton S; DiNardo CD; Fathi AT; Schuh AC; Montesinos P; Vyas P; Prebet T; Gandhi A; Hasan M
    Leuk Res; 2024 May; 140():107497. PubMed ID: 38564986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.
    Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW
    Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273
    [No Abstract]   [Full Text] [Related]  

  • 31. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
    Pollyea DA; Tallman MS; de Botton S; Kantarjian HM; Collins R; Stein AS; Frattini MG; Xu Q; Tosolini A; See WL; MacBeth KJ; Agresta SV; Attar EC; DiNardo CD; Stein EM
    Leukemia; 2019 Nov; 33(11):2575-2584. PubMed ID: 30967620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In brief: Two new drugs for AML.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
    [No Abstract]   [Full Text] [Related]  

  • 33. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
    Kallen ME; Koka R; Singh Z; Sanchez-Petitto G; Zaman QU; Yared JA; Duong VH
    Leuk Res; 2020 Sep; 96():106406. PubMed ID: 32604058
    [No Abstract]   [Full Text] [Related]  

  • 36. Integrating Full Bayesian Inference and Student's t-Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug-Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS Patients.
    Cheng Y; Du S; Hu H; Wang X; Carayannopoulos L; Li Y
    J Clin Pharmacol; 2024 Jul; 64(7):866-877. PubMed ID: 38478303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
    Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W; Kovacsovics T; Blum WG; Schiller GJ; Olin RL; Foran JM; Litzow M; Lin T; Patel P; Foster MC; Boyiadzis M; Collins RH; Chervin J; Shoben A; Vergilio JA; Heerema NA; Rosenberg L; Chen TL; Yocum AO; Druggan F; Marcus S; Stefanos M; Druker BJ; Mims AS; Borate U; Burd A; Byrd JC; Levine RL; Stein EM
    Blood Adv; 2024 Jan; 8(2):429-440. PubMed ID: 37871309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Ghosh A; Pu J; Carayannopoulos LN; Li Y
    J Clin Pharmacol; 2024 Aug; 64(8):984-992. PubMed ID: 38563070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.